Insider Selling: Progyny (NASDAQ:PGNY) EVP Sells $10,506.46 in Stock

Progyny, Inc. (NASDAQ:PGNY) EVP Allison Swartz sold 599 shares of the stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $17.54, for a total transaction of $10,506.46. Following the sale, the executive vice president directly owned 88,941 shares of the company’s stock, valued at approximately $1,560,025.14. This trade represents a 0.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Allison Swartz also recently made the following trade(s):

• On Tuesday, March 3rd, Allison Swartz sold 4,657 shares of Progyny stock. The shares were sold at an average price of $17.40, for a total transaction of $81,031.80.
• On Monday, March 2nd, Allison Swartz sold 2,199 shares of Progyny stock. The stock was sold at an average price of $17.27, for a total transaction of $37,976.73.

Progyny Stock Performance

Shares of NASDAQ:PGNY opened at $18.31 on Monday. The firm has a market cap of $1.50 billion, a price-to-earnings ratio of 28.17, a P/E/G ratio of 1.22 and a beta of 1.01. The firm has a fifty day moving average price of $23.09 and a 200 day moving average price of $22.93. Progyny, Inc. has a fifty-two week low of $16.75 and a fifty-two week high of $28.75.

Progyny (NASDAQ:PGNY) last announced its quarterly earnings results on Thursday, February 26th. The company reported $0.48 EPS for the quarter, topping the consensus estimate of $0.38 by $0.10. Progyny had a net margin of 4.54% and a return on equity of 11.37%. The business had revenue of $318.40 million for the quarter, compared to analysts’ expectations of $314.26 million. During the same quarter in the previous year, the company earned $0.42 EPS. The business’s quarterly revenue was up 6.7% compared to the same quarter last year. Progyny has set its FY 2026 guidance at 1.830-1.950 EPS and its Q1 2026 guidance at 0.420-0.450 EPS. As a group, research analysts predict that Progyny, Inc. will post 0.6 earnings per share for the current year.

Institutional Investors Weigh In On Progyny

Several institutional investors have recently modified their holdings of the stock. California State Teachers Retirement System increased its position in shares of Progyny by 0.7% during the 2nd quarter. California State Teachers Retirement System now owns 70,421 shares of the company’s stock valued at $1,549,000 after purchasing an additional 457 shares during the last quarter. Teza Capital Management LLC lifted its position in Progyny by 5.4% in the second quarter. Teza Capital Management LLC now owns 10,068 shares of the company’s stock worth $221,000 after buying an additional 516 shares during the last quarter. Leibman Financial Services Inc. boosted its stake in Progyny by 1.2% during the fourth quarter. Leibman Financial Services Inc. now owns 46,435 shares of the company’s stock worth $1,192,000 after buying an additional 528 shares during the period. Aristides Capital LLC boosted its stake in Progyny by 4.6% during the third quarter. Aristides Capital LLC now owns 11,938 shares of the company’s stock worth $257,000 after buying an additional 528 shares during the period. Finally, Oxford Asset Management LLP increased its position in Progyny by 4.3% during the second quarter. Oxford Asset Management LLP now owns 12,918 shares of the company’s stock valued at $284,000 after acquiring an additional 531 shares during the last quarter. 94.93% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts recently commented on PGNY shares. Zacks Research lowered Progyny from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 30th. Wall Street Zen raised Progyny from a “hold” rating to a “buy” rating in a research note on Saturday, January 3rd. Barclays began coverage on Progyny in a report on Monday, December 8th. They set an “overweight” rating and a $29.00 price objective on the stock. Citigroup upgraded Progyny to an “outperform” rating in a research report on Tuesday, January 20th. Finally, BTIG Research cut their target price on shares of Progyny from $35.00 to $30.00 and set a “buy” rating for the company in a report on Thursday. Nine research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Progyny currently has an average rating of “Moderate Buy” and a consensus target price of $29.09.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.